November 2019 - Present
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate to-Severe Atopic Dermatitis.

Febrero 2020 - Present
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU- for the Treatment of Chronic Pruritis in Adult Subjects with Atopic Dermatitis.

March 2020 - Present
A rambdomized, Double Blind Placebo- controlled study to asses the efficacy and safety of Nemolizumab in subjects with Prurigo Nodularis.

May 2019 - Present
Galderma, Phase III Pivotal Study and Open Label Extension to Assess the Efficacy and Safety of Nemolizumab in Moderate to Severe Atopic Dermatitis Subjects and Associated Pruritus.

March 2019 - Present
RE; GD-268-001.
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects with Acne Vulgaris.

February 2017 - January 2018
71542613.
Open-Label Safety to Assess the Multiple Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment with “Halobetasol Propionate 0.05% Topical Spray” (Sun Pharmaceuticals Industries Limited) in Patients with Moderate to Severe Atopic

February 2017 - January 2018
71542611.
Randomized, Double-Blind, Vehicle Controlled, Parallel Design, Multiple Site Clinical Study to Evaluate the Efficiency and Safety of “Halobetasol Propionate 0.05% Topical Spray” (Sun Pharmaceuticals Industries Limited) in Patients with Moderate to Severe.

February 2016 - February 2017
SC1402.
Clinical, Randomized, Multi-Center, Placebo Controlled Study to Evaluate the Efficacy and Safety of 1.5 Milligram and/or Kilogram Per Day of Sarecycline Compared to Placebo in the Treatment of Vulgaris.

September 2014 - January 2015
CIM003JG.
Chugai Pharmaceutical, Phase II, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of CIM331 in Atopic Dermatitis Patients Who Are Inadaquately Controlled or Intolerant to Topical Therapy.

June 2008 - April 2009
M10-315 ABBOTT.
Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects.

April 2008 - October 2011
M10-016 ABBOTT.
Phase III, Multi-Center, Open Label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Proceeding Psoriasis Study with ABT-874.

January 2008 - June 2009
M06-890 ABBOTT.
Phase III, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.

February 2004 - February 2006
Multi-Center, Open Label, Perspective Studies to Evaluate the Effectiveness and Safety of Etanercept in the Treatment in Psoriasis.

August 1998
M.Muhart & M.Rendon & A.Pedrozo III Tazorac for Treatment of Psoriasis.

August 1998
M.Muhart & M.Rendon & A.Pedrozo III Lentigines Survey & Treatment; Herbal Cream vs. Placebo on Hands.

August 1998
M.Muhart & M.Rendon & A.Pedrozo III Lentingines Treatment; Herbal Cream vs. Hydroquinone Cream 2% on Hands.

February 1992
M.Rendon & A.Pedrozo III Use of Alpha Hydroxyl Acids on Lentingines.

August 1991
Soto & Pedrozo. Monoclonal Antibodies in the Diagnosis of Leishmaniasis.

August 1990
Sexually Transmitted Diseases.

April 1989
Dermatoses in Colombian Soldiers.

April 1988
Etiology & Management of Leg Ulcers.